Glow-in-the-Dark dye could reveal hidden heart attack risk

NCT ID NCT06957821

Not yet recruiting Diagnosis Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a fluorescent dye called LUMISIGHT (pegulicianine) can light up inflammation in artery plaques removed during surgery. Inflammation is a key driver of heart attacks, but current imaging can't see it clearly. Researchers will compare the dye to a placebo in 25 people with severe carotid or peripheral artery disease. If the dye works, it might one day help doctors identify high-risk plaques before they cause problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pegulicianine (LUMISIGHT) dye
What this could lead to: If successful, this could lead to a new way to see dangerous inflammation in arteries, helping doctors better predict and prevent heart attacks.
What could go wrong: This is a very early, small study (25 people) testing the dye on removed tissue, not in living patients. It may not work as hoped or translate to real-time imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAROTID ARTERY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carotid artery disorder peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAROTID ARTERY DISEASES PERIPHERAL ARTERIAL DISEASE

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.